ORP 101
Alternative Names: Buprenorphine dimer - OrphoMed; ORP-101Latest Information Update: 06 Jan 2022
At a glance
- Originator OrphoMed
- Class Cyclopropanes; Irritable bowel syndrome therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Irritable bowel syndrome
Most Recent Events
- 04 Jan 2022 Safety and efficacy data from the phase II PREVAIL trial in Irritable bowel syndrome released by OrphoMed
- 30 Nov 2021 OrphoMed completed phase II PREVAIL trial in Irritable bowel syndrome (In adults, In the elderly) in USA (PO, Tablet) by November 2021
- 28 Feb 2021 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome in USA (IV, Injection)